Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Express Scripts
Mallinckrodt
AstraZeneca

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Arbekacin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Arbekacin?

Arbekacin is an investigational drug.

There have been 5 clinical trials for Arbekacin. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Pneumonia, Muscular Dystrophy, Duchenne, and Muscular Dystrophies. The leading clinical trial sponsors are Meiji Seika Pharma Co., Ltd., U.S. Army Medical Research and Development Command, and U.S. Army Medical Research and Materiel Command.

There are eight hundred and thirty-two US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for Arbekacin
TitleSponsorPhase
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial PneumoniaMeiji Seika Pharma Co., Ltd.Phase 1
Intrapulmonary Pharmacokinetics of ME1100 in Healthy VolunteersMeiji Seika Pharma Co., Ltd.Phase 1
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular DystrophyJapan Medical AssociationPhase 2

See all Arbekacin clinical trials

Clinical Trial Summary for Arbekacin

Top disease conditions for Arbekacin
Top clinical trial sponsors for Arbekacin

See all Arbekacin clinical trials

US Patents for Arbekacin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Arbekacin ⤷  Try it Free Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Try it Free
Arbekacin ⤷  Try it Free Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Try it Free
Arbekacin ⤷  Try it Free Composition including rapamycin as active ingredient for preventing or treating hearing loss AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Suwon-si, Gyeonggi-do, KR) ⤷  Try it Free
Arbekacin ⤷  Try it Free Nucleic acid vaccines ModernaTX, Inc. (Cambridge, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Arbekacin

Drugname Country Document Number Estimated Expiration Related US Patent
Arbekacin Australia AU2011210567 2030-01-29 ⤷  Try it Free
Arbekacin Canada CA2787784 2030-01-29 ⤷  Try it Free
Arbekacin European Patent Office EP2528893 2030-01-29 ⤷  Try it Free
Arbekacin European Patent Office EP3138838 2030-01-29 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Express Scripts
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.